Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A randomized, parallel, multicenter, active-controlled with 48 weeks of treatment period.
Patients will be randomized to receive clevudine alone for 48 weeks or clevudine for 24 weeks
followed by 24 weeks of clevudine in addition to monthly HBV vaccination.The purpose of this
study is to investigate efficacy of combination of clevudine and HBV vaccine over clevudine
alone in patients with chronic hepatitis B infection.